NASDAQ:BLFS - BioLife Solutions Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $17.53 -0.10 (-0.57 %) (As of 05/26/2019 04:00 PM ET)Previous Close$17.53Today's Range$17.28 - $17.8252-Week Range$9.15 - $26.35Volume79,103 shsAverage Volume158,696 shsMarket Capitalization$329.55 millionP/E Ratio125.21Dividend YieldN/ABeta1.53 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioLife Solutions, Inc. develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death. The company offers CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing; and HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 to cryopreserve stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including cell and gene therapy companies, research institutions, hospital-based stem cell transplant centers, cell therapy contract manufacturing organizations, contract development manufacturing organizations, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington. Receive BLFS News and Ratings via Email Sign-up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLFS Previous Symbol CUSIPN/A CIK834365 Webhttp://www.biolifesolutions.com/ Phone425-402-1400Debt Debt-to-Equity Ratio0.02 Current Ratio14.50 Quick Ratio12.99Price-To-Earnings Trailing P/E Ratio125.21 Forward P/E Ratio134.85 P/E GrowthN/A Sales & Book Value Annual Sales$19.74 million Price / Sales16.69 Cash Flow$0.1617 per share Price / Cash Flow108.42 Book Value$2.36 per share Price / Book7.43Profitability EPS (Most Recent Fiscal Year)$0.14 Net Income$3.27 million Net Margins17.01% Return on Equity10.32% Return on Assets9.64%Miscellaneous Employees54 Outstanding Shares18,799,000Market Cap$329.55 million Next Earnings Date8/8/2019 (Estimated) OptionableNot Optionable BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions What is BioLife Solutions' stock symbol? BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS." How were BioLife Solutions' earnings last quarter? BioLife Solutions Inc (NASDAQ:BLFS) issued its quarterly earnings results on Thursday, May, 9th. The medical equipment provider reported $0.03 EPS for the quarter, hitting the consensus estimate of $0.03. The medical equipment provider had revenue of $5.77 million for the quarter, compared to analysts' expectations of $5.67 million. BioLife Solutions had a net margin of 17.01% and a return on equity of 10.32%. View BioLife Solutions' Earnings History. When is BioLife Solutions' next earnings date? BioLife Solutions is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for BioLife Solutions. What guidance has BioLife Solutions issued on next quarter's earnings? BioLife Solutions updated its FY 2019 earnings guidance on Thursday, March, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $27-30 million, compared to the consensus revenue estimate of $28.04 million. What price target have analysts set for BLFS? 4 analysts have issued 12-month target prices for BioLife Solutions' shares. Their predictions range from $5.00 to $24.00. On average, they anticipate BioLife Solutions' stock price to reach $17.25 in the next year. This suggests that the stock has a possible downside of 1.6%. View Analyst Price Targets for BioLife Solutions. What is the consensus analysts' recommendation for BioLife Solutions? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioLife Solutions. What are Wall Street analysts saying about BioLife Solutions stock? Here are some recent quotes from research analysts about BioLife Solutions stock: 1. Maxim Group analysts commented, "On 5/9, BioLife reported 1Q19 with $5.8M in revenue, up 51% y/y and 6% sequentially, with a gross margin of 71.5%. BioLife also reported a $0.4M net profit for the quarter and ended the period with $31.8M in cash. We note that this does not include revenues from the Astero Acquisition (completed in April)." (5/22/2019) 2. According to Zacks Investment Research, "BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. " (5/15/2019) 3. Northland Securities analysts commented, "We continue to believe BioLife is one of the better small-cap plays with a lower risk exposure to the biotech / regen med space. Maintain OP rating." (5/13/2019) Has BioLife Solutions been receiving favorable news coverage? News coverage about BLFS stock has been trending somewhat negative on Sunday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BioLife Solutions earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of BioLife Solutions' key competitors? Some companies that are related to BioLife Solutions include Natus Medical (BABY), AxoGen (AXGN), Viewray (VRAY), TransMedics Group (TMDX), Semler Scientific (SMLR), Rockwell Medical (RMTI), Cutera (CUTR), Zynex (ZYXI), Stereotaxis (STXS), BioSig Technologies (BSGM), Fonar (FONR), Edap Tms (EDAP), Second Sight Medical Products (EYES), IRIDEX (IRIX) and electroCore (ECOR). What other stocks do shareholders of BioLife Solutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Canopy Growth (CGC), Twilio (TWLO), NVIDIA (NVDA), Cara Therapeutics (CARA), Terra Tech (TRTC), Micron Technology (MU), Square (SQ), Exelixis (EXEL), Juno Therapeutics (JUNO) and Progenics Pharmaceuticals (PGNX). Who are BioLife Solutions' key executives? BioLife Solutions' management team includes the folowing people: Mr. Michael P. Rice, Pres, CEO & Director (Age 56)Mr. Roderick de Greef, CFO & Sec. (Age 59)Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Chief Technology Officer and Sr. VP (Age 47)Ms. Karen Foster, VP of Operations (Age 59)Mr. Kevin O'Donnell, VP of Cold Chain Standards, Practices & Compliance Who are BioLife Solutions' major shareholders? BioLife Solutions' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.66%), Essex Investment Management Co. LLC (1.60%), Schonfeld Strategic Advisors LLC (1.46%), BlackRock Inc. (1.27%), Cadence Capital Management LLC (1.05%) and FMR LLC (0.80%). Company insiders that own BioLife Solutions stock include Andrew G Hinson, Greef Roderick De, Joseph C Schick, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger. View Institutional Ownership Trends for BioLife Solutions. Which major investors are selling BioLife Solutions stock? BLFS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Essex Investment Management Co. LLC and Northern Trust Corp. Company insiders that have sold BioLife Solutions company stock in the last year include Andrew G Hinson, Greef Roderick De, Joseph C Schick, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger. View Insider Buying and Selling for BioLife Solutions. Which major investors are buying BioLife Solutions stock? BLFS stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Quantum Capital Management, Roubaix Capital LLC, Laurion Capital Management LP, ExodusPoint Capital Management LP, Tibra Equities Europe Ltd and Granite Investment Partners LLC. View Insider Buying and Selling for BioLife Solutions. How do I buy shares of BioLife Solutions? Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioLife Solutions' stock price today? One share of BLFS stock can currently be purchased for approximately $17.53. How big of a company is BioLife Solutions? BioLife Solutions has a market capitalization of $329.55 million and generates $19.74 million in revenue each year. The medical equipment provider earns $3.27 million in net income (profit) each year or $0.14 on an earnings per share basis. BioLife Solutions employs 54 workers across the globe. What is BioLife Solutions' official website? The official website for BioLife Solutions is http://www.biolifesolutions.com/. How can I contact BioLife Solutions? BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected] MarketBeat Community Rating for BioLife Solutions (NASDAQ BLFS)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 180 (Vote Outperform)Underperform Votes: 128 (Vote Underperform)Total Votes: 308MarketBeat's community ratings are surveys of what our community members think about BioLife Solutions and other stocks. Vote "Outperform" if you believe BLFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLFS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: Straddles Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.